Premium
Recommendations for the clinical and laboratory diagnosis of VITT against COVID‐19: Communication from the ISTH SSC Subcommittee on Platelet Immunology
Author(s) -
Nazy Ishac,
Sachs Ulrich J.,
Arnold Donald M.,
McKenzie Steven E.,
Choi Phil,
Althaus Karina,
Ahlen Maria Therese,
Sharma Ruchika,
Grace Rachael F.,
Bakchoul Tamam
Publication year - 2021
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.15341
Subject(s) - medicine , pandemic , covid-19 , immunology , immune system , adverse effect , intensive care medicine , virology , infectious disease (medical specialty) , disease , outbreak
Vaccine administration is under way worldwide to combat the current COVID‐19 pandemic. The newly developed vaccines are highly effective with minimal adverse effects. Recently, the AstraZeneca ChadOx1 nCov‐19 vaccine has raised public alarm with concerns regarding the rare, but serious, development of thrombotic events, now known as vaccine‐induced immune thrombotic thrombocytopenia (VITT). These thrombotic events appear similar to heparin‐induced thrombocytopenia, both clinically and pathologically. In this manuscript, the ISTH SSC Subcommittee on Platelet Immunology outlines guidelines on how to recognize, diagnose and manage patients with VITT.